Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Head and Neck, Carcinoma, Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Durvalumab, Tremelimumab, AZD9150, MEDI4736, AZD5069, tremelimumab (treme), AZD9150 / MEDI4736, AZD5069 / MEDI4736, AZD5069/MEDI4736, AZD9150/Treme/MEDI4736, AZD5069/Treme/MEDI4736, AZD9150/MEDI4736
Lead Scientist at UCSF
- Alain Algazi
Dr. Alain Algazi is a specialist in medical treatment – such as chemotherapy and immunotherapy – for patients with head and neck cancers, including head and neck squamous cell carcinoma, thyroid cancers and salivary gland cancers. He leads UCSF's program in medical therapy for head and neck cancers, and chairs the head and neck cancer research committee.